This article is more than 5 years old. Information may no longer be current.

Ocriplasmin approved for treatment of vitreomacular traction in European Union

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The European Commission approved ocriplasmin to treat vitreomacular traction in the European Union, according to a press release from ThromboGenics.

The approval, which includes cases in which vitreomacular traction is associated with a macular hole with a diameter of 400 µm or less, results in Alcon making a €45 million milestone payment to ThromboGenics. Another €45 million milestone payment will be made upon the first sale of Jetrea (ocriplasmin, ThromboGenics) in the EU, the release said.

ThromboGenics controls the commercialization of ocriplasmin in the United States, where it was approved by the U.S. Food and Drug Administration to treat symptomatic vitreomacular traction in October 2012. The product was launched in the U.S. in January.

Alcon, a division of Novartis, paid ThromboGenics €75 million in March 2012 for the rights to ocriplasmin outside the U.S. Long-term potential payments of the deal are expected to reach €375 million, with Alcon intending to introduce ocriplasmin in more than 40 countries.